Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969952 | 0.86 | HTR6 (0.53) | HTR6MPOKDM4EALDH1A1TDP1 | |
| SCHEMBL3147363 | 0.82 | HTR6 (0.52) | HTR6MPOKDM4EALDH1A1TDP1 | |
| SCHEMBL3147357 | 0.82 | HTR6 (0.52) | HTR6MPOKDM4EALDH1A1TDP1 | |
| SCHEMBL4970421 | 0.80 | HTR6 (0.50) | HTR6MPOKDM4EALDH1A1TDP1 | |
| SCHEMBL5659589 | 0.78 | HTR6 (0.53) | HTR6MPOHTR1AHTR1DHTR1B | |
| SCHEMBL28805276 | 0.77 | HTR6 (0.62) | HTR6MPOKDM4EALDH1A1TDP1 | |
| SCHEMBL4004572 | 0.76 | HTR6 (0.54) | HTR6MPO | |
| Water SCHEMBL28867170 | 0.74 | HTR6 (0.80) | HTR6MPOKDM4EALDH1A1TDP1 | |
| SCHEMBL19252920 | 0.73 | RPS6KA3 (0.49) | HTR6MPOAURKAAURKBKDM4E | |
| SCHEMBL948662 | 0.72 | HTR6 (1.00) | HTR6MPOKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081600-B1 | Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2012-12-05 | — | — | EP | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| EP-1666462-B1 | N-[1H-INDOL-5-YL]NAPHTHALENE-1-SULPHONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | ESTEVE LABOR DR (ES) | 2009-04-15 | — | — | EP | claimed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| WO-2009013010-A2 | 5HT6-LIGANDS SUCH AS SULFONAMIDE DERIVATIVES IN DRUG- INDUCED WEIGHT-GAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | WO | claimed |
| EP-2018861-A1 | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-28 | — | — | EP | claimed |
| CN-100441180-C | Use of sulfonamide derivatives as ligands for 5-ht6, in treatment of e.g. food ingestion disorder, obesity, bulimia, anorexia, cachexia and type ii diabetes | PARATEK PHARM INNC (ES) | 2008-12-10 | — | — | CN | claimed |
| EP-1626715-B1 | USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | ESTEVE LABOR DR (ES) | 2008-09-10 | — | — | EP | claimed |
| US-7176200-B2 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2007-02-13 | — | — | US | claimed |
| CN-1271052-C | Sulfonamide derivatives, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2006-08-23 | — | — | CN | claimed |
| CN-1816334-A | Use of sulfonamide derivatives as ligands for 5-ht6, in treatment of e.g. food ingestion disorder, obesity, bulimia, anorexia, cachexia and type ii diabetes | PARATEK PHARM INNC (ES) | 2006-08-09 | — | — | CN | claimed |
| EP-1666462-A1 | N-[1H-INDOL-5-YL]NAPHTHALENE-1-SULPHONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-07 | — | — | EP | claimed |
| US-20050065202-A1 | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-03-24 | — | — | US | claimed |
| CN-1599718-A | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | ESTEVE LABOR DR (ES) | 2005-03-23 | — | — | CN | claimed |
| EP-1445252-A1 | SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-08-11 | — | — | EP | claimed |
| US-20030191124-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-10-09 | — | — | US | claimed |
| EP-2081600-B1 | Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2012-12-05 | — | — | EP | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| WO-2004098588-A1 | USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2004-11-18 | — | — | WO | disclosed |
| EP-1445252-A1 | SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065202-A1 | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion | SULT2A1, STS, MPST | HTR6 886/4885MPO 1588/4885MLNR 432/4885 |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | HTR6 1/4885MPO 4731/4885MLNR 276/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | HTR6 1/4885MPO 2376/4885MLNR 128/4885 |
| US-20030191124-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | STS, SULT2A1, MPST | HTR6 3229/4885MPO 1144/4885MLNR 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.